 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
|
|
|
|
Phase III
|
|
|
|
SWOG-S0337
S0337, NCT00445601
|
|
| |
Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
WBPDT-577-04
NCT00322699
|
|
| |
E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
|
|
|
|
Phase II, Phase I
|
|
|
|
CCC-PHII-75
7435, NCI-7435, NCT00365157
|
|
| |
Phase I & II Trial of Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
AAAC1114
NCT00583349
|
|
| |
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
|
|
|
|
Phase II
|
|
|
|
MDA-ID-030111
NCT00082706
|
|
| |
Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
|
|
|
|
Phase II
|
|
|
|
SWOG-S0353
S0353, NCT00234039
|
|
| |
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
|
|
|
|
Phase II
|
|
|
|
HOG GU04-75
NCT00234494
|
|
| |
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
|
|
|
|
Phase II
|
|
|
|
MUSC-AVF-3312
100892, MUSC-HR-15537, GENENTECH-AVF-3312, NCT00268450, MUSC-CTO-100892
|
|
| |
Randomized Phase II Study for Patients With Previously Treated Advanced Urothelial Cancer
|
|
|
|
Phase II
|
|
|
|
FER-GU-004
NCT00350025
|
|
| |
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
|
|
|
|
Phase II
|
|
|
|
MSKCC-06081
NCT00397488
|
|
